Market Place
Sourcing Support
Immatics Announces 4 Oral Sessions in Cell Therapy at 2026 ASCO
21 Apr 2026 //
FIRSTWORD PHARMA
Immatics` TCR Achieves Remission in Children with Nephroblastoma
19 Apr 2026 //
FIRSTWORD PHARMA
Immatics Reveals 2025 Financials And Business Progress
05 Mar 2026 //
GLOBENEWSWIRE
Immatics Reveals Positive IMA203CD8 PRAME Cell Therapy Data
11 Dec 2025 //
GLOBENEWSWIRE
Immatics Reveals Q3 2025 Financials And Business Progress
17 Nov 2025 //
GLOBENEWSWIRE
Immatics Hits TCER Milestone with IMA402 & IMA401
12 Nov 2025 //
GLOBENEWSWIRE
Immatics Appoints Amie Krause As Chief People Officer
27 Oct 2025 //
GLOBENEWSWIRE
Immatics Shows Anzu-cel Activity in Metastatic Uveal Melanoma
20 Oct 2025 //
GLOBENEWSWIRE
Immatics Appoints Venkat Ramanan As Chief Financial Officer
01 Oct 2025 //
GLOBENEWSWIRE
Immatics IMA203 PRAME Cell Therapy Data at 2025 ASCO
31 May 2025 //
GLOBENEWSWIRE
Immatics to Present IMA203 TCR Therapy at 2025 ASCO Meeting
23 Apr 2025 //
GLOBENEWSWIRE
Immatics Reports 2024 Financial Results and Business Update
27 Mar 2025 //
GLOBENEWSWIRE
Bristol Myers culls cell therapy deals with 2 biotechs
17 Dec 2024 //
FIERCE BIOTECH
Immatics Announces Q3 2024 Results & First Data on TCER® IMA402
18 Nov 2024 //
GLOBENEWSWIRE
Immatics Announces TCR-T Therapy PRAME Targets at 39th SITC
08 Nov 2024 //
GLOBENEWSWIRE
Immatics leaps into phase 3 on strength of early-stage PFS data
10 Oct 2024 //
FIERCE BIOTECH
Immatics Updates On IMA203 TCR-T In Melanoma And SUPRAME Trial
10 Oct 2024 //
GLOBENEWSWIRE
Immatics Announces Proposed $150 Million Public Offering
10 Oct 2024 //
GLOBENEWSWIRE
Immatics Announces Pricing of $150 Million Public Offering
10 Oct 2024 //
GLOBENEWSWIRE
Immatics Announces Presentations At SITC Annual Meeting 2024
04 Oct 2024 //
GLOBENEWSWIRE
Immatics Presents TCER IMA401 Phase 1 Data At ESMO 2024
16 Sep 2024 //
GLOBENEWSWIRE
Immatics To Give Oral Presentation At Melanoma Research Congress 2024
06 Sep 2024 //
GLOBENEWSWIRE
Immatics Reports Interim Clinical Data from ACTengine® IMA203
08 Nov 2023 //
GLOBENEWSWIRE
Immatics Receives FDA RMAT Designation for ACTengine® IMA203 TCR-T Monotherapy
24 Oct 2023 //
GLOBENEWSWIRE
Moderna, Immatics Ink Potential $1.8B Oncology Deal including Cancer Vaccines
12 Sep 2023 //
BIOSPACE
Immatics Initiates Phase 1/2 Trial to Evaluate PRAME TCR Bispecific IMA402
10 Aug 2023 //
GLOBENEWSWIRE
Immatics spikes on a round of promising but still early autologous cell therapy
02 May 2023 //
ENDPTS
